Solid Biosciences: 1.5-Year Data from Ongoing Duchenne Phase I/II Trial

 Data support continued functional benefit 1.5 years post treatment compared with natural history data; assessed by North Star Ambulatory Assessment (NSAA), 6-Minute Walk Test (6MWT) and Forced Vital Capacity (FVC) -

- Patient reported outcomes showed sustained improvements at 1.5 years compared to patient baseline and natural history data -

- No new drug-related safety findings for a period of up to 3.5 years -

https://finance.yahoo.com/news/solid-biosciences-reports-1-5-100000387.html